[{"orgOrder":0,"company":"Vensica Therapeutics","sponsor":"Merz Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"IncobotulinumtoxinA","moa":"SNAP25","graph1":"Urology","graph2":"Phase III","graph3":"Vensica Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"Vensica Therapeutics \/ Merz Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vensica Therapeutics \/ Merz Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Vensica Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : This investment follows the strategic license and collaboration agreement signed in 2021 to utilize Merz’s botulinum neurotoxin A (XEOMIN®) for the innovative ultrasound-assisted delivery catheter of Vensica.

                          Brand Name : Xeomin

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 07, 2022

                          Lead Product(s) : IncobotulinumtoxinA

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Merz Therapeutics

                          Deal Size : $19.0 million

                          Deal Type : Partnership

                          blank